Characteristics and outcomes of 627 044 COVID-19 patients with and without obesity in the United States, Spain, and the United Kingdom

Introduction

Obesity is associated with increased mortality and is a well-known risk factor of chronic conditions, such as diabetes, hypertension, cardiovascular disease and, cancer.¹ Due to its proinflammatory state that impairs the immune response, obesity has also been related to increased risk of viral infections, including seasonal influenza.²

The novel coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been compared to seasonal influenza in terms of symptoms and complications.³ Both viruses cause respiratory tract infection with clinical manifestations ranging from asymptomatic/mild symptoms to severe illness requiring intensive services. Partly due to its similarities with influenza, people with obesity were soon labelled as “at-risk” individuals.⁴ Recent studies have found that obesity is common among severe and fatal COVID-19 cases.^5-8 In hospitalized cohorts from the United States (US), obesity prevalence in COVID-19 cases ranges from 40 to 50%,^9-11 while lower prevalence has been reported in non-hospitalized cases. A primary care study from Spain found that 20% of COVID-19 cases were obese,¹² while in a population-based study from Denmark only 9% were obese.¹³

Since obesity is a worldwide public health priority, granular information on obese patients with COVID-19 is needed to guide preventive strategies.¹⁴ In this study, we aimed to describe and compare the demographics, comorbidities, and outcomes of obese patients with COVID-19 to those of 1) non-obese patients with COVID-19, and 2) obese patients with seasonal influenza, among inpatient or outpatient settings.

Methods

Results

Baseline comorbidities

In the diagnosed cohorts, obese patients with COVID-19 consistently had a higher prevalence of comorbidities compared to non-obese patients (upper part of Figure 1.A and Supplementary table 4). For example, while the prevalence of hypertension for the obese ranged from 30% to 32% in Europe (CPRD and SIDIAP) and from 55% to 81% in the US, in the non-obese it ranged from 12% to 16% and from 26 to 53%, respectively. When compared to obese patients with influenza, obese patients with COVID-19 had a higher prevalence of comorbidities for SIDIAP, STARR-OMOP, and IQVIA-OpenClaims whereas they had fewer comorbidities for CPRD and CUIMC (Figure 1.B, Supplementary table 6).

• Download figure
• Open in new tab

• Download figure
• Open in new tab

Figure 1: Previous comorbidities: a comparison between obese and non-obese patients with COVID-19 and obese influenza patients

A. Obese and non-obese COVID-19 patients

Prevalence of comorbidities for obese (red) and non-obese (blue) patients are depicted in overlapped horizontal bars. Grey colour is the overlap between groups (therefore, it shows the lowest value). For example, in CPRD, 32% of obese and 16% of non-obese patients have hypertension.

B. Obese patients with COVID-19 or with Influenza

Prevalence of comorbidities for obese COVID-19 (red) and obese Influenza (green) patients are depicted in overlapped horizontal bars. Grey colour is the overlap between groups (lowest value).

As in the diagnosed cohort, hospitalized obese patients with COVID-19 had a higher prevalence of comorbidities than non-obese; however, the differences between groups were less obvious (lower part of Figure 1.A., Supplementary table 5). For example, heart disease differed by 20% among those diagnosed in VA-OMOP (obese: 60%, non-obese: 40%) and by 9% among those hospitalized (obese: 74%, non-obese: 65%). Contrary to the findings for the diagnosed cohort, hospitalized obese patients with influenza had a higher prevalence of comorbidities compared to COVID-19 patients (lower part of Figure 1.B., Supplementary table 6), except for mental health conditions which were higher in COVID-19 patients in some databases (anxiety in SIDIAP and VA-OMOP and dementia in IQVIA-OpenClaims and VA-OMOP).

30-day outcomes of interest

In the diagnosed cohorts, hospitalizations rates were higher among obese COVID-19 patients than among non-obese and obese influenza patients in all databases (Figure 2). For example, in IQVIA-OpenClaims, the proportion of patients hospitalized was 32% and 26% for obese and non-obese patients with COVID-19 and 9% for obese patients with influenza. Among obese COVID-19 patients, fatality ranged from 5% to 12%. While CPRD and VA-OMOP had similar fatality in obese and non-obese; in SIDIAP and CUIMC, obese patients had a higher fatality than non-obese (7% vs 3% and 8% vs 5%, respectively). Among obese COVID-19 patients, fatality was higher than among obese influenza patients (range: 0·1% to 3%).

• Download figure
• Open in new tab

• Download figure
• Open in new tab

Figure 2: Main outcomes: a comparison between obese and non-obese patients with COVID-19 and obese influenza patients

A. Obese and non-obese COVID-19 patients

B. Obese COVID-19 and obese influenza patients

In the hospitalized cohorts, obese patients with COVID-19 required intensive services more frequently than non-obese in STARR-OMOP (obese: 9% vs non-obese: 6%), IQVIA-OpenClaims (13% vs 10%) and VA-OMOP (22% vs 15%). Percentages in CUIMC were too small to assess differences (2·3% vs 2·0%). Hospitalized obese patients with COVID-19 also required intensive services more often than obese patients with influenza in IQVIA-OpenClaims (13% vs 3%) and VA-OMOP (22% vs 6%) whereas in CUIMC (2% vs 6%) the opposite was observed.

There were no notable differences in fatality between obese and non-obese hospitalized patients with COVID-19: 14% vs 11% in SIDIAP, 20% vs 21% in CUIMC and 16% vs 18% in VA-OMOP. However, fatality among obese COVID-19 cases was much higher than among obese influenza patients (2% in CUIMC and 4% in VA-OMOP).

Overall, obese patients with COVID-19 had adverse events occurring in the 30 days after the index date more frequently than non-obese (Table 2). This was especially evident for the most frequent events, namely acute respiratory distress syndrome (ARDS) (range: 15% to 46% among obese, range: 10% to 41% among non-obese) and heart failure (7% to 23% among obese, 3% to 17% among non-obese) during hospitalization. Sepsis, cardiac arrhythmia, and total cardiovascular disease events were also slightly more frequent among obese COVID-19 patients compared to non-obese. Acute kidney injury was the only outcome that was more frequent among non-obese; however, except for CUIMC, differences were small. For the rest of the reported events, numbers were too small to assess differences between obese and non-obese COVID-19 patients.

View this table:

• View inline
• View popup
• Download powerpoint

Table 2: 30-day events in obese and non-obese patients hospitalized with COVID-19

Discussion

In this large cohort including 627 044 COVID-19 and 4 549 568 influenza patients from the US, Spain, and the UK, we found that the prevalence of obesity was higher among COVID-19 patients hospitalized compared to those diagnosed and was higher in both COVID-19 cohorts compared to the influenza cohorts. Obese patients diagnosed and hospitalized with COVID-19 were more commonly female, and presented with more comorbidities and adverse outcomes than non-obese patients. Although obese COVID-19 patients were younger and less likely to have comorbidities than obese influenza patients in the hospitalized cohorts, they more frequently had adverse outcomes.

Given the prevalence of obesity in the US (37%), the UK (27%) and Spain (24%), a high proportion of obese patients among COVID-19 cases was expected.²² However, the prevalence of obesity among COVID-19 patients was higher than the general population in the three countries, which is suggestive of an increased risk of diagnosis in obese patients. Obese individuals could be more likely to seek care and be tested for SARS-CoV-2 since they are a high-risk, multimorbid population and could be more prone to respiratory symptoms due to their compromised pulmonary function. Alternatively, they might have an increased risk of COVID-19 infection that could be explained through differences in exposure and/or vulnerability. Two studies from Spain and the UK found a higher risk of being diagnosed with COVID-19 in obese individuals.^7,23 We also found a higher proportion of obesity among hospitalized COVID-19 patients compared to those diagnosed. The prevalence of obesity from this study was similar to three cohort studies from the US that reported 40%, 42% and 48% of hospitalized patients were obese.^9-11 These findings could reflect a preferential care in high-risk populations but also an increased risk of severe disease among obese patients.

Prior characterization studies from the hospital setting have consistently reported that COVID-19 hospitalized patients are more frequently male.^10,11 We found, however, that women predominate among hospitalized obese patients. Since the prevalence of obesity is similar for men and women in the three countries, our findings could reflect that obesity is a greater risk factor for hospitalization among women compared to men.²² Some of the biological hypotheses that have been posited to explain the greater risk of poor COVID-19 outcomes among men are similar to those proposed for obese individuals. For example, one hypothesis argues that sex differences in the immune response increase men’s vulnerability. Men have higher levels of interleukin-6 and tumour necrosis factor alpha, which are the main drivers of the phenomenon of “cytokine storm” that has been observed in severe COVID-19 patients.^24,25 Obese individuals also have higher levels of these pro-inflammatory cytokines.²⁶ Similarly, men have higher levels of angiotensin-converting enzyme 2, which are also elevated in obese individuals.^25,27

We also found that compared to non-obese, patients with obesity were older among those diagnosed with COVID-19 and younger in those hospitalized. The former observation might be explained by the early identification of both older age and obesity as risk factors for COVID-19.⁴ This could have increased the frequency of testing among people with these characteristics. Conversely, the differences observed in the hospital setting could be related to a greater risk of severe outcomes among individuals with obesity younger than 60.²⁸ Although younger individuals have less risk of infections and complications than older people due to having fewer comorbidities and a stronger immune system,^29,30 this is not the case for obese individuals.^31,32 Therefore, the more fragile health of obese patients even in the young may contribute to the observed age pattern for the individuals hospitalized with obesity.

Obese individuals differed also in terms of comorbidities. Unsurprisingly, the highest differences were observed in obesity-related conditions, such as hypertension, diabetes, and heart disease, which have been identified as risk factors for severe COVID-19 outcomes.^7,8,10,13 The selected comorbidities likely represent only a small proportion of the differences that should be considered when assessing the links between obesity and COVID-19. For instance, obesity is strongly interlinked with socioeconomic status and ethnicity, and disproportionately affects disadvantaged populations.²⁹ In the US, the prevalence of obesity is higher among Hispanic and African Americans than among their White counterparts. These disparities have been hypothesized as a contributing factor explaining ethnic differences in the proportion of hospitalizations.³³ Given the links between obesity and the social determinants of health, obese individuals might be more at risk of COVID-19 infection and complications due to more precarious working conditions and barriers in healthcare access. Unfortunately, due to data unavailability, we could not directly explore socioeconomic status or ethnicity differences in our study.

Finally, obese individuals experienced more frequently adverse events than non-obese, including hospitalization and requirement of intensive services. These results, however, must be interpreted carefully considering the differences in socio-demographics and comorbidities between obese and non-obese individuals. Despite this limitation, our results are in line with previous studies where obesity was associated with an increased risk of hospitalization and mortality, adjusting for sex, age, and comorbidities.^7,8,10,13 Given the scarcity of evidence regarding the frequency of specific adverse events during hospitalization among obese patients, our findings are of special interest to the field and should be addressed in upcoming associative studies.

Since obesity has been associated with different forms of influenza, an association with COVID-19 was expected from the beginning of the pandemic.³⁴ Interestingly, we found that the prevalence of obesity was higher among both COVID-19 diagnosed and hospitalized patients compared to those with seasonal influenza, which may be suggestive of an inherent vulnerability towards COVID-19 among obese patients. In both COVID-19 and influenza cohorts, female sex was more frequent than male sex. A large study comparing hospitalized patients with COVID-19 to those with influenza found that COVID-19 patients were predominantly male whereas those with influenza were mostly women.³⁵ While our study replicated those findings for non-obese patients, we observed that women predominated among obese patients hospitalized with COVID-19. Thus, our results provide a finer picture of the most frequent sex of patients with COVID-19 among those with obesity. Older age has been associated with an increased risk of more severe forms of both COVID-19 and influenza,³ however, we observed obese patients with COVID-19 were younger than those with influenza. Our findings are in line with previous studies that reported younger ages among individuals with H1N1 and COVID-19 compared to seasonal influenza (obese and non-obese individuals together).^35,36 Finally, although obese patients diagnosed with COVID-19 had more comorbidities than obese influenza patients the opposite was observed among hospitalized patients. This could reflect either a higher virulence of SARS-CoV-2 compared to influenza or a differential pattern in clinical practice, with a lower threshold for hospitalization in COVID-19 cases. However, obese patients with COVID-19 consistently had worse outcomes than influenza patients. These results put in to question the justification that worse outcomes among obese patients with COVID-19 are merely due to a higher prevalence of co-existing conditions.³⁷

Our study has several strengths, such as its large amount of data. This study contains information on 627 044 COVID-19 cases from six databases of three different countries and provides a wide overview of the characteristics and outcomes of patients with and without obesity. Almost 29 000 unique aggregate characteristics were generated and made publicly available. This was accomplished through the coordinated efforts of the OHDSI community to provide a rapid response to the COVID-19 pandemic. We employed a federated analysis approach that allowed us to respect the confidentiality of patient records at all times, and we emphasized transparency throughout the study, making methods, tools, and results publicly available.

Our study also has limitations. One limitation is its descriptive nature. Since we aimed to characterize and compare patients with and without obesity, statistical tests and modelling were out of scope in the developed analytical packages. However, our findings were consistent across databases. In addition, the exhaustive characterization performed in this study supports the generation of new hypotheses that can be tested in detail in future studies. Second, we cannot exclude a selection bias of COVID-19 cases due to underreporting in the context of testing restrictions and asymptomatic or paucisymptomatic cases that usually do not seek medical care. Additionally, testing policies have varied across countries and time depending on the course of the pandemic. The inclusion of COVID-19 cases clinically diagnosed (without being tested) in different countries and settings likely provided consistency to our data, although it might have incurred in false positives. Third, we did not have information on BMI as a continuous variable, which prevented us from investigating the impact of different categories of obesity in COVID-19 outcomes. This might explain the higher proportion of comorbidities and outcomes observed in the US databases, as obese individuals from the US might be more obese than those from Europe. Fourthly, we cannot discard that the differences found in the COVID-19/seasonal influenza comparison may have been influenced by temporal changes in clinical practice standards and coding. Further, the use of influenza vaccination among high-risk population groups likely contributed to the observed low proportion of adverse events among influenza patients.³⁸ Finally, this study was underpinned by routinely-collected data which can raise concerns about the quality of the data. Some databases are prone to oversampling certain groups of people as a result of how these data are captured (e.g. the Veterans Affairs system historically serves more men than women, routine claims data may only reflect health outcomes in commercially insured populations, etc). Obesity, comorbidities, and outcomes were assessed based on having a record of a condition/measurement, therefore they may be underestimated. Even still, the consistency of our findings across several databases that differ by setting and country lends credence to the generalizability of our findings.

In this large international cohort, we showed that obese patients with COVID-19 were more likely to be female, had more comorbidities and worse outcomes than non-obese patients. We provide novel evidence that the prevalence of obesity is higher among COVID-19 patients compared to those with seasonal influenza and that obese hospitalized COVID-19 patients have worse outcomes than obese patients with influenza, despite presenting with fewer comorbidities. Our results may be useful in guiding clinical practice and aid future preventative strategies for obese individuals, as well as providing useful data to support subsequent association studies focussed on obesity and COVID-19.

Ethical approval

All the data partners received Institutional Review Board (IRB) approval or exemption. STARR-OMOP had approval from IRB Panel #8 (RB-53248) registered to Leland Stanford Junior University under the Stanford Human Research Protection Program (HRPP). The use of VA data was reviewed by the Department of Veterans Affairs Central IRB, was determined to meet the criteria for exemption under Exemption Category 4(3), and approved for Waiver of HIPAA Authorization. The research was approved by the Columbia University Institutional Review Board as an OHDSI network study. The use of SIDIAP was approved by the Clinical Research Ethics Committee of the IDIAPJGol (project code: 20/070-PCV). The use of CPRD was approved by the Independent Scientific Advisory Committee (ISAC) (protocol number 20_059RA2). The use of IQVIA-OpenClaims was exempted from IRB approval.

Competing interest statement

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: Mr. Sena reports personal fees from Janssen Research & Development, outside the submitted work; Dr. DuVall reports grants from Anolinx, LLC, grants from Astellas Pharma, Inc, grants from AstraZeneca Pharmaceuticals LP, grants from Boehringer Ingelheim International GmbH, grants from Celgene Corporation, grants from Eli Lilly and Company, grants from Genentech Inc., grants from Genomic Health, Inc., grants from Gilead Sciences Inc., grants from GlaxoSmithKline PLC, grants from Innocrin Pharmaceuticals Inc., grants from Janssen Pharmaceuticals, Inc., grants from Kantar Health, grants from Myriad Genetic Laboratories, Inc., grants from Novartis International AG, grants from Parexel International Corporation through the University of Utah or Western Institute for Biomedical Research, outside the submitted work; Mr Ahmed reports funding from the NIHR Oxford Biomedical Research Centre (BRC), Aziz Foundation, Wolfson Foundation, and the Royal College Surgeons of England; Dr. Golozar reports personal fees from Regeneron Pharmaceuticals, outside the submitted work. She is a full-time employee at Regeneron Pharmaceuticals. This work was not conducted at Regeneron Pharmaceuticals. Miss Lane is supported by a Medical Research Council Doctoral Research Fellowship (MR/K501256/1) and a Versus Arthritis Clinical Research Fellowship (21605). Dr. Morales is supported by a Wellcome Trust Clinical Research Development Fellowship (Grant 214588/Z/18/Z) and reports grants from Chief Scientist Office (CSO), grants from Health Data Research UK (HDR-UK), grants from National Institute of Health Research (NIHR), outside the submitted work; Dr. Nyberg reports other from AstraZeneca, outside the submitted work; Dr. Subbian reports grants from National Science Foundation, grants from State of Arizona; Arizona Board of Regents, grants from Agency for Healthcare Research and Quality, outside the submitted work; Dr Prieto-Alhambra reports grants and other from AMGEN; grants, non-financial support and other from UCB Biopharma; grants from Les Laboratoires Servier, outside the submitted work; and Janssen, on behalf of IMI-funded EHDEN and EMIF consortiums, and Synapse Management Partners have supported training programs organized by DPA’s department and open for external participants. Ms. Kostka and Dr. Reich report being employees of IQVIA Inc. Dr. Ryan is an employee of Janssen Research and Development and shareholder of Johnson & Johnson. The views expressed are those of the authors and do not necessarily represent the views or policy of the Department of Veterans Affairs or the United States Government. No other relationships or activities that could appear to have influenced the submitted work.

Transparency declaration

Lead authors affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

Contributorship statement

MR, ER, APU, PR, DPA, KK and TDS conceived and designed the study. SLD, TF, KEL, MEM, KN, JDP, CGR, NHS, PR, KK and TDS coordinated data contributions at their respective sites. AP, AGS, TF, SFB, JDP, KK and TDS analyzed the data; MR, ER and AP produced the figures and tables. MR, ER, EB, DRM, FN, PR, LMS, DPA, KK and TDS interpreted the data. MR, ER and TDS searched the literature and wrote the first draft with insightful contributions from EB, LYHL, JCEL, DRM, FN, PR, LMS, DPA and KK. All authors contributed to the revision of the first draft, reviewed and approved the final version of the manuscript.

Data sharing statement

Analyses were performed locally in compliance with all applicable data privacy laws. Although the underlying data is not readily available to be shared, authors contributing to this paper have direct access to the data sources used in this study. All results (e.g. aggregate statistics, not presented at a patient-level with redactions for minimum cell count) are available for public inquiry. These results are inclusive of site-identifiers by contributing data sources to enable interrogation of each contributing site. All analytic code and result sets are made available at: https://github.com/ohdsi-studies/Covid19CharacterizationCharybdis

Abbreviations

ARDS

Acute Respiratory Distress Syndrome

BMI

Body Mass Index

CDM

Common Data Model

COVID-19

Coronavirus disease 2019

CPRD

Clinical Practice Research Datalink

CUIMC

Columbia University Irving Medical Center

EHR

Electronic Health Record

IRB

Institutional Review Board

OHDSI

Observational Health Data Sciences and Informatics

OMOP

Observational Medical Outcomes Partnership

SARS-CoV-2

severe acute respiratory syndrome coronavirus 2

SIDIAP

Information System for Research in Primary Care

SNOMED

Systematized Nomenclature of Medicine

STARR-OMOP

Stanford Medicine Research Data Repository

UK

United Kingdom

US

United States

VA-OMOP

United States Department of Veterans Affairs

WHO

World Health Organization